AIM
AXDX icon

Arcadia Investment Management’s Accelerate Diagnostics AXDX Stock Holding History

Arcadia Investment Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-65
Closed -$16K – 370
2017
Q1 		$16K Buy
+65
New +$14.8K 0.01% 343

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Polar Capital
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Arcadia Investment Management's AXDX Position: Q2 2017 in Review

Arcadia Investment Management sold out of Accelerate Diagnostics (AXDX) in Q2 2017, closing a stake of 65 shares — an estimated $16K sold.

Arcadia Investment Management first reported a position in AXDX in Q1 2017 and held it in 1 quarter. The position peaked at $16K in Q1 2017. 119 funds tracked by Wall St. Rank hold AXDX as of Q2 2017.

  • Arcadia Investment Management reported no remaining Accelerate Diagnostics position as of Q2 2017 after selling out during the quarter.
  • Arcadia Investment Management sold 65 Accelerate Diagnostics shares in Q2 2017, an estimated $16K.
  • Arcadia Investment Management first reported a position in Accelerate Diagnostics in Q1 2017 and held it in 1 quarter.
  • Arcadia Investment Management's Accelerate Diagnostics position peaked at $16K in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2017.

Based on Arcadia Investment Management's 13F filing for Q2 2017, filed 3 Aug 2017.